Tag: GlobeNewswire

MANITOWOC, Wis., Oct. 06, 2026 (GLOBE NEWSWIRE) — Orion Energy Systems, Inc. (NASDAQ: OESX) (Orion Lighting), a provider of energy-efficient LED lighting, electric vehicle (EV) charging station and maintenance service solutions, announced today that it will be featured and meeting with customers at the Mingo Facilities Management Solutions Summit October 25-27 at the Atlanta Airport Marriott at 4711 Best Road in Atlanta, GA.

The summit is a gathering of high-level executives to discuss the most advanced developments in facilities management. Among the most prominent concentrations at the event are lighting, IoT solutions and EV charging infrastructure, which are particular areas of focus for Orion and Voltrek, the company’s EV charging group.

More information about the summit may be obtained at https://mingosummits.com/events/FM-Solutions-Summit/Oct-25-2026.

Orion/Voltrek will also be participating and meeting with customers at a number of additional industry events in the coming weeks, including:

October 4-7, 2026
APTA TRANSform & Expo 
McCormick Place 
12 E. Cerman Rd, Chicago, IL 60616 
APTA 2026 TRANSform & EXPO – APTA
APTA’s TRANSform & EXPO is where the world of public transportation converges to explore cutting-edge technology, innovative mobility solutions, and the future of the industry. As the largest showcase of its kind, EXPO elevates the next era of global transit driven by advanced technologies, sustainable solutions, and forward-thinking business models.

October 11-14, 2026
The NALMCO Annual Convention and Trade Show 
Renaissance Phoenix Glendale Hotel & Conference Center
9495 W. Entertainment Blvd., Glendale, AZ.
https://whova.com/web/TtMkhEYB1a08OLbFLGTJX-xPhsf4vmPFo1gtD6yvy0A=/
The National Association of Lighting Management Companies (NALMCO) Annual Convention and Trade Show is a three-day event held each October, bringing together lighting management professionals from across the United States. The convention attracts an average of 250 attendees and 50 exhibitors, creating a focused yet dynamic environment for learning, networking, and business development.

October 15, 2026, 9 a.m. – 2 p.m. ET
The Boston Buildings & Facility Maintenance Show
Shriners’ Auditorium
Wilmington, MA.
https://maintenanceshowsboston.com/
The show is among the leading events for plant & facility engineering, plant management and buildings engineering & facility maintenance professionals from the New England region.

October 25-28, 2026
EEI National Key Accounts Fall 2026 Workshop
Hyatt Regency Orlando
9801 International Drive
Orlando, FL.
The semi-annual workshop is one of the premier events of the Edison Electric Institute, which represents all investor-owned utilities in the United States.

November 4-6, 2026
The Society of American Military Engineers (SAME)
Federal Small Business Conference for the A/E/C Industry 2026
Charlotte Convention Center
501 S College Street, Charlotte, N.C.
The event brings together SAME public and private-sector members focusing on engineering, construction, facility management and related disciplines in support of national security.

November 17-19, 2026
National Association of Energy Service Companies (NAESCO)
2026 Annual R3 Conference and Innovation Expo
Grand Hyatt San Antonio River Walk
San Antonio, TX.
NAESCO was established in 1983 to provide a unified voice for the emerging energy savings performance contracting industry and to educate the market about the value of performance-based energy solutions. Annually, NAESCO gathers leaders and experts within the energy service company industry for a multi-day event to discuss new policies, strategies and technologies.

Interested attendees wishing to meet with Orion/Voltrek at these events may contact Suzana Gusa at sgusa@oesx.com and (312) 660-3573.

About Orion Energy Systems (at www.orionlighting.com)
Orion provides energy efficient LED lighting and controls, electrical vehicle (EV) charging solutions, and electrical maintenance services. Orion specializes in turnkey design-through-installation solutions for large national customers as well as projects through ESCO and distribution partners. Orion is committed to helping customers achieve their business, financial and environmental goals with high quality, innovative and safe solutions delivered with high levels of customer service and reliability.

Engage with Us
X: @OrionLighting and @OrionLightingIR
StockTwits: @OESX_IR

Investor Relations Contacts
Per Brodin, CFO	Robert Ferri
Orion Energy Systems, Inc.	Robert Ferri Partners
pbrodin@oesx.com	(415) 575-1589 robert.ferri@robertferri.com

• Newly created award category highlights innovation in prescription skin treatment
• ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award
• ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis

WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE^® (roflumilast) cream 0.15% was presented with the 2026 “Best Prescription Skin Solution” Award by Marie Claire magazine. The magazine created this award category as part of its Marie Claire US Beauty Awards to recognize medical innovation in bringing advanced skin solutions to consumers. ZORYVE is the first prescription medication to win this award and is being recognized for the innovation it offers to people with mild to moderate atopic dermatitis (eczema) 6 years of age and older.

“The launch of Marie Claire’s Best Prescription Skin Solution Award recognizes something important: innovation in skincare doesn’t stop at the beauty counter. Prescription therapies can fundamentally change the experience of living with a chronic inflammatory skin disease, and that impact should not be understated,” said Mona Shahriari, MD, Associate Clinical Professor of Dermatology at Yale School of Medicine, and Associate Director of Clinical Trials at CCD Research. “As the inaugural recipient, ZORYVE exemplifies the kind of innovation this new category was created to recognize. ZORYVE is a non-steroidal treatment option that helps individuals with eczema achieve clearer skin and itch relief, with a formulation designed with the skin barrier in mind and without ingredients known to compromise it. That matters, because in eczema, restoring and protecting the skin barrier isn’t secondary to treatment — it’s central to it.”

Atopic dermatitis, the most common form of eczema, is a lifelong relapsing, inflammatory skin condition that commonly presents as a red, inflamed rash and affects over 26 million in the U.S.

“We are proud that ZORYVE cream 0.15% for eczema has been named the winner of Marie Claire’s Best Prescription Skin Solution Award,” said Frank Watanabe, president and chief executive officer of Arcutis. “This new category, dedicated specifically to prescription skin solutions, is recognition of the innovation happening in medical dermatology, and being selected as its first recipient is an incredible honor. ZORYVE was developed to address the most complex and persistent challenges faced by people living with chronic inflammatory skin diseases, and this award is recognition of our commitment to developing advanced targeted topical therapies that help individuals with these conditions, including eczema.”

This marks the third major beauty award honoring ZORYVE, adding to accolades from Allure’s 2025 Best of Beauty Breakthrough Award for ZORYVE cream 0.15%, ZORYVE cream 0.3%, and ZORYVE topical foam 0.3% and Glamour’s 2024 Beauty and Wellness Award for “Best Eczema Product,” which also recognized ZORYVE cream 0.15%.

Simone Biles recently partnered with Arcutis to launch the Skin to Believe In campaign, helping to raise awareness of chronic inflammatory skin diseases, including eczema, and encouraging people to talk to their doctor about treatment options. 

ZORYVE is a once-daily, steroid-free topical foam or cream that can be used anywhere on the body, for any duration, and is suitable for all skin and hair types in its respective approved indications. ZORYVE’s novel, water-based, non-greasy formulation has moisturizing properties and contains no penetration enhancers, ceramide-stripping properties, fragrances, ethanol, or propylene glycol.

For more information including prescribing information, visit www.zoryve.com.

A Media Snippet accompanying this announcement is available by clicking on this link.

About ZORYVE^® (roflumilast)
ZORYVE is the number one prescribed branded topical therapy across three major inflammatory dermatoses combined — atopic dermatitis (eczema), seborrheic dermatitis, and plaque psoriasis. ZORYVE is a topical formulation of roflumilast, an advanced targeted topical phosphodiesterase type 4 (PDE4) inhibitor. Inhibiting PDE4, an intracellular enzyme that is an established target in dermatology, decreases the production of pro-inflammatory mediators. This decreases inflammation in the skin and balances the skin’s immune system.

Demonstrating both clinical impact and broad industry recognition, ZORYVE has been honored with multiple prestigious awards, including three from major beauty magazines:

• Allure’s “2025 Best of Beauty Breakthrough Award,” making it the first FDA-approved medication for atopic dermatitis, plaque psoriasis, and seborrheic dermatitis to win this prominent award;
• Glamour’s 2024 Beauty and Wellness Award for “Best Eczema Product,” recognizing ZORYVE cream 0.15%;
• And most recently, Marie Claire’s “2026 Best Prescription Skin Solution” Award, recognizing ZORYVE cream 0.15% for eczema.

In addition, ZORYVE has been honored with the following recommendations:

• National Psoriasis Foundation’s Seal of Recognition for ZORYVE cream 0.3% and ZORYVE foam 0.3% — the first FDA-approved prescription brand to receive the honor. 
• American Academy of Dermatology (AAD) issued a strong recommendation for the use of ZORYVE cream 0.15% in adults with mild to moderate atopic dermatitis, in updated guidelines released June 2025, as well as a strong recommendation for the use of ZORYVE cream 0.05% for children aged 2-5 years and ZORYVE cream 0.15% for children aged 6 years and older with mild to moderate atopic dermatitis from the AAD’s first-ever pediatric atopic dermatitis guidelines published in April 2026.

INDICATIONS
ZORYVE cream, 0.05%, is indicated for topical treatment of mild to moderate atopic dermatitis in pediatric patients 2 to 5 years of age.

ZORYVE cream, 0.15%, is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older.

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.

ZORYVE topical foam, 0.3%, is indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older.

IMPORTANT SAFETY INFORMATION
ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C).

Flammability: The propellants in ZORYVE foam are flammable. Avoid fire, flame, and smoking during and immediately following application.

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.05% for pediatric patients with atopic dermatitis 2 to 5 years of age were upper respiratory tract infection (4.1%), diarrhea (2.5%), vomiting (2.1%), rhinitis (1.6%), conjunctivitis (1.4%), and headache (1.1%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.15% for patients with atopic dermatitis 6 years of age or older were headache (2.9%), nausea (1.9%), application site pain (1.5%), diarrhea (1.5%), and vomiting (1.5%).

The most common adverse reactions reported (≥1%) for ZORYVE cream 0.3% for plaque psoriasis were diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for plaque psoriasis were headache (3.1%), diarrhea (2.5%), nausea (1.7%), and nasopharyngitis (1.3%).

The most common adverse reactions reported (≥1%) for ZORYVE foam 0.3% for seborrheic dermatitis were nasopharyngitis (1.5%), nausea (1.3%), and headache (1.1%).

Please see full Prescribing Information for ZORYVE foam and full Prescribing Information for ZORYVE cream.

ZORYVE is for topical use only and not for ophthalmic, oral, or intravaginal use.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X. 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding the potential for ZORYVE to advance the standard of care in atopic dermatitis, plaque psoriasis, and seborrheic dermatitis. These statements are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.

Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com

Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Vesuvius Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	01/10/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	10p Ordinary Shares
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	3,000,870	1.20%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	3,000,870	1.20%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
10p Ordinary Shares	Sale	1,390	465.4206p

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
10p Ordinary Shares

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	06/10/2026
Contact name:	Nicky Vaughan – Compliance Department
Telephone number:	0151 243 7224

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

Proof of concept transported and remotely released a 300-pound amphibious vehicle that subsequently transited from offshore to the beach

MONROE TOWNSHIP, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or the “Company”) (NYSE American: OPTT), a leader of maritime operational infrastructure and autonomous ocean systems, today announced the successful completion of a proof of concept requested by Greensea IQ involving the offshore deployment of the amphibious Bayonet 150 Autonomous Underwater Ground Vehicle (AUGV) from a modified WAM-V^® 16 unmanned surface vessel.

OPT modified the WAM-V 16 to transport and deploy the 300-pound Bayonet 150. During the test, the WAM-V carried the vehicle offshore, initiated a remotely triggered release, and safely deployed its umbilical. After deployment, Bayonet operated under Greensea IQ’s control system and completed its transit from the offshore release point to the beach.

The proof of concept focused on transport, deployment, and safe separation between vehicles. Bayonet is designed for amphibious and surf-zone operations relevant to mine countermeasures and other littoral missions. “Greensea IQ brought us a specific deployment challenge: transport a 300-pound amphibious vehicle offshore and release it safely for independent transit to the beach,” said Jason Weed, Chief Operating Officer of OPT. “We modified the WAM-V 16 to support the vehicle, its remotely triggered deployment, and its umbilical. Completing that sequence demonstrates the value of WAM-V as adaptable mobile infrastructure for specialized partner systems.”

“Paired with a Bayonet 150 AUGV, the WAM-V USV can now take on seabed missions with greater flexibility. The Bayonet Autonomous Ground Vehicle (AUGV) deploys straight from the USV’s open chassis, creating one unmanned system that can cover the surface and work the seabed in the same mission” said Paco Santana, VP of Business Development for Greensea IQ.

Tracy Pagliara, Acting President and CEO of OPT, added: “We believe the test demonstrates WAM-V 16’s role as a modular surface transport and deployment platform. Rather than owning every component of an operation, our WAM-V can be adapted to carry and deploy specialized systems developed and controlled by mission partners.”

For more information about Ocean Power Technologies, visit www.OceanPowerTechnologies.com.

ABOUT OCEAN POWER TECHNOLOGIES

OPT provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets, including Merrows™, which provides AI capable seamless integration of Maritime Domain Awareness Systems across platforms. Our PowerBuoy^® platforms provide clean and reliable electric power and real-time data communications for remote maritime and subsea applications. We also provide WAM-V^® unmanned surface vessels (USVs) and marine robotics services. The Company’s headquarters is in Monroe Township, New Jersey, with an additional office in Richmond, California. To learn more about OPT’s products, services and solutions, visit www.OceanPowerTechnologies.com.

FORWARD-LOOKING STATEMENTS

This release may contain forward-looking statements that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates that could be inaccurate and subject to risks and uncertainties, the further development and integration of WAM-V and Bayonet platforms for naval mine clearance operations, the conversion of potential customers to contracts and the realization of the potential revenue thereunder. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the U.S. Securities and Exchange Commission for further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

Contact Information

Investors: 203-561-6945 or investorrelations@oceanpowertech.com

Media: 609-730-0400 x402 or MediaRelations@oceanpowertech.com

Turbo Energy’s systems integrate battery storage, solar generation and industrial demand through intelligent energy management at three sites under the Company’s previously announced $53 million contract to supply and implement 366 MWh of battery storage

Turbo Energy’s battery storage technology integrated with rooftop solar at one of the industrial sites included in Pamesa Net Zero, enabling intelligent management of renewable energy for industrial operations.

VALENCIA, Spain, Oct. 06, 2026 (GLOBE NEWSWIRE) — Turbo Energy, S.A. (Nasdaq: TURB) (“Turbo Energy” or the “Company”), a global technology integrator specializing in AI-driven energy storage and energy management solutions, today announced that 62.5 MWh of intelligent energy storage capacity supplied by the Company is now fully operational across three industrial sites in Spain: ECO Porcelánico, Compacglass and TAU Porcelánico. The systems have completed installation, commissioning and testing and are currently being used in normal commercial operations.

The operating systems form part of Turbo Energy’s previously announced $53 million contract to supply and implement 366 MWh of battery storage across 10 factories. The transition of the first three sites into full operation demonstrates the project’s progression from equipment delivery and installation to the active management of energy under real industrial production conditions.

At the three operating sites, Turbo Energy’s storage technology and intelligent energy management system coordinate battery charging and discharging with photovoltaic generation and each facility’s industrial consumption profile. Based on project operating data, the three sites combine 62.5 MWh of fully operational battery storage with 34 MWp of installed and operating photovoltaic capacity.

This integrated architecture enables solar generation, battery storage and industrial demand to operate as a coordinated energy system. Turbo Energy’s energy management technology continuously monitors the performance of these assets and manages how stored energy is used according to the operating requirements of each factory.

From delivery to industrial operation

During the first half of 2026, Turbo Energy delivered more than 130 MWh of battery storage systems for the project. With 62.5 MWh now fully operational, the Company has advanced a material portion of that delivered capacity through installation, system integration and commissioning into active industrial operation. The remaining delivered capacity is at various stages of installation, system integration and commissioning and is not included in the 62.5 MWh operational figure.

This progression represents an important execution step for Turbo Energy. The project requires the Company’s storage technology and proprietary energy management system to be deployed across multiple industrial sites with different consumption profiles, production schedules and technical configurations, demonstrating its capacity to integrate distributed storage systems at scale.

Since the first systems entered operation in July 2026, the three operating installations have avoided 421 metric tons of CO₂, providing an initial measured indication of the environmental performance of the integrated energy infrastructure.

“Bringing 62.5 MWh online is the point at which delivered equipment becomes an actively managed industrial energy asset,” said Mariano Soria, Chief Executive Officer of Turbo Energy. “These systems are now coordinating battery storage, solar generation and factory demand under real production conditions. This progress demonstrates our ability to execute complex, multi-site storage projects and provides a strong operating reference for future commercial and industrial deployments.”

Intelligent Energy Management at industrial scale

The three operating sites form part of Pamesa Net Zero, a broader industrial energy platform being developed across the facilities of Pamesa Grupo Empresarial, one of Europe’s leading ceramic manufacturing groups. The broader project is being developed by Umbrella Global Energy, Turbo Energy’s parent company, through IM2 Energía Solar, another subsidiary of Umbrella Global Energy. Under the previously announced $53 million contract, Turbo Energy is responsible for supplying and implementing the battery storage technology and proprietary AI-driven energy management system that connect the project’s generation, storage and industrial consumption assets within a coordinated architecture.

At each site, the energy management system analyzes real-time and forecast electricity prices, weather forecasts, expected solar generation, predicted facility demand, battery status and operating constraints. It uses these inputs to determine when energy should be stored, drawn from the grid or deployed from the batteries, supporting increased renewable self-consumption, more efficient asset utilization and greater control over each facility’s energy requirements.

As additional sites advance through delivery, installation and commissioning, Turbo Energy expects to extend this operating model across the wider project. The remaining deployment schedule is subject to construction readiness, permitting, testing, customer acceptance and other project-specific conditions.

Pamesa Net Zero provides an operating reference for Turbo Energy’s ability to deliver integrated storage and energy management across complex industrial environments. This capability is also reflected in the Company’s separate $3.5 million portfolio of 15 intelligent energy storage projects across Spain and Chile, announced in September 2026, which extends Turbo Energy’s technology across a diversified range of commercial and industrial applications.
About Turbo Energy, S.A.

Founded in 2013, Turbo Energy, S.A. (Nasdaq: TURB) is a global technology integrator specializing in AI-driven energy storage and energy management solutions. The Company integrates advanced battery storage, proprietary software and energy management systems into intelligent energy solutions that help residential, commercial and industrial customers optimize energy consumption, reduce costs, improve resilience and maximize the value of their energy assets.

As part of Umbrella Global Energy, Turbo Energy plays a strategic role in driving innovation in intelligent energy storage, electrification and software-defined energy management across Europe, North America and Latin America. For more information, please visit www.turbo-e.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, including anticipated manufacturing, delivery, installation and commissioning timelines, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of the business of the Company, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control, including the risks described in the Company’s registration statements and annual reports under the heading “Risk Factors” as filed with the Securities and Exchange Commission. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Turbo Energy, S.A. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, please contact:                 

Turbo Energy | Investor Relations
Email: investors@turbo-e.com
Website: investors.turbo-e.com

Attachment

• Turbo Energy’s battery storage technology integrated with rooftop solar at one of the industrial sites included in Pamesa Net Zero, enabling intelligent management of renewable energy for industrial operations.

Gasoline-powered platform designed for more than four hours of hover endurance advances through prototype assembly, adding a long-endurance, heavy-payload capability to ZenaTech’s counter-UAS portfolio alongside the Interceptor P-1

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech” or the “Company”), a technology solution provider specializing in AI-powered drones, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, provides an update on the ZenaDrone 2000, its heavy-lift autonomous interceptor designed to counter hostile drones and coordinated swarm attacks over land and sea. ZenaDrone is building the first full prototype and part of an integrated defense system, at its facility in Sharjah, UAE, and now expects to begin flight testing in the first quarter of 2027.

Recent build milestones include:

• Airframe and folding arm structure completed
• Gasoline propulsion system and 36-inch propellers bench-tested
• Flight controller and autonomy software in ground testing

Once assembly is complete, the first flight test phase will validate takeoff, hover and landing at full and partial payload, endurance toward the 4+ hour hover rating, the 360-degree detection system, and autonomous navigation. Later phases are expected to add autonomous threat pursuit, multi-target engagement, swarm coordination with the Interceptor P-1, and maritime launch and recovery from ZenaDrone’s IQ Glider marine launch and refueling station.

Specification	ZenaDrone 2000
Max takeoff weight	200 kg
Payload capacity	40 kg
Hover endurance	4+ hours
Propulsion	Gasoline, 4 × 36-inch propellers
Sensors	Cameras providing 360-degree coverage
Footprint (folded / deployed)	224.8 × 82.0 cm / 180.4 × 365.8 cm

The ZenaDrone 2000 is designed to fill a gap between small, single-use interceptors and costly missile-based air defense. Its long endurance capability allows it to stay airborne over a base, port, vessel or border crossing for hours, while its 40 kg payload supports heavier sensors and counter-drone effectors. Paired with the low-cost Interceptor P-1, which recently began its own flight testing, it is designed to give defense customers a layered system: the ZenaDrone 2000 watches and coordinates, and P-1 interceptors engage.

“The ZenaDrone 2000 is the largest and most capable aircraft we have built, and we are taking the time to get the prototype right before it flies,” said Shaun Passley, Ph.D., CEO of ZenaTech. “Militaries, navies and border agencies need counter-drone systems that can stay on station for hours and respond to many threats at once, at a cost they can field at scale. With the Interceptor P-1 already inflight testing and the ZenaDrone 2000 moving through its build, we are assembling a complete, affordable counter-UAS layer for the U.S., our allies and partners in the Middle East for a counter-UAS market that industry analysts indicate could exceed USD $20 billion by 2030.”

Recent conflicts across the Middle East and beyond have exposed a glaring imbalance in modern air defense economics. Gulf nations and their allies have been forced to deploy interceptor missiles costing hundreds of thousands — or even millions — of dollars to destroy drones from hostile nations that could be valued at $20,000. This unsustainable cost asymmetry is being exploited by adversaries who can field swarms of low-cost, slow-moving aerial threats faster than conventional defense systems can economically respond. The global defense community has recognized that the most practical, scalable, and affordable answer to the drone threat is not another expensive missile — it is a better, smarter, faster drone.

ZenaTech expects to announce further updates on the ZenaDrone 2000 as milestones are achieved and as the prototype build is complete.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries including land surveys and inspections, driving drone-based scalable and recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for agriculture and logistics, as well as ISR, cargo, and counter-UAS applications for U.S. defense and NATO allies. The company is investing in next-generation technologies, including drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets through its R&D initiatives.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, and the IQ Aqua for underwater applications. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing counter-UAS maritime interceptor drones and an integrated defense system.

Contacts for more information:

Company, Investors, and Media: Linda Montgomery ZenaTech 312-241-1415 investors@zenatech.com

Investors: Michael Mason CORE IR investors@zenatech.com

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated; ZenaTech’s ability to develop products for markets as currently contemplated; ZenaTech’s anticipated cash needs and its needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech and other related risks and uncertainties disclosed under the heading “Risk Factors” in the Company’s Form F-1, Form 20-F and other filings filed with the United States Securities and Exchange Commission (the “SEC”) on EDGAR through the SEC’s website at www.sec.gov. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser:	Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):         The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	Vesuvius Plc
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e)   Date position held/dealing undertaken:         For an opening position disclosure, state the latest practicable date prior to the disclosure	29/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?         If it is a cash offer or possible cash offer, state “N/A”	No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	10p Ordinary Shares
	Interests		Short positions
	Number	%	Number	%
(1)   Relevant securities owned and/or controlled:	3,002,260	1.20%
(2)   Cash-settled derivatives:
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	3,002,260	1.20%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchase/sale	Number of securities	Price per unit
10p Ordinary Shares

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
10p Ordinary Shares

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i)   the voting rights of any relevant securities under any option; or (ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:	06/10/2026
Contact name:	Nicky Vaughan – Compliance Department
Telephone number:	0151 243 7224

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

• After a scheduled interim analysis of the severe babesiosis study on October 1, 2026, the DSMB recommended completing the study with the originally planned number of patients (N=33); the study remains blinded
• As of the same date, the Company had enrolled 30 patients
• Given the limited incremental statistical power from enrolling three additional patients and the seasonal nature of babesiosis, which would otherwise delay unblinding until fall 2027, the Company has decided to conclude enrollment and proceed with unblinding. Primary and secondary endpoint results are expected in January 2027
• No safety signals were identified in the study
• Published case reports and the Company’s prospective expanded access study support the potential of tafenoquine-containing regimens in treatment-refractory, relapsing babesiosis, and additional data will be disclosed from this study in early November 2026
• Company sees a viable regulatory pathway for severe and/or treatment-refractory disease and will request a pre-sNDA meeting with FDA in January 2027 to discuss data requirements, patient population, regulatory pathway, and post-marketing requirements

WASHINGTON, Oct. 06, 2026 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it intends to conclude enrollment in its randomized clinical study of tafenoquine in patients hospitalized with severe babesiosis at 30 subjects. The Company plans to unblind the study and report its primary and secondary endpoint results in January 2027, and to submit a request for a pre- supplemental New Drug Application (sNDA) meeting with the U.S. Food and Drug Administration (FDA) that same month.

60 Degrees is the sponsor of the double-blind, randomized, multisite, placebo-controlled clinical trial entitled “Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis” (NCT06207370), which is evaluating the efficacy and safety of tafenoquine in treating severe babesiosis in humans. Patients were enrolled at multiple sites in the U.S., including Tufts Medical Center, Rhode Island Hospital, Yale University, Brigham and Women’s Hospital, and Westchester Medical Center.

The DSMB conducted an interim analysis of time to sustained clinical resolution of babesiosis, the study’s primary endpoint, and time to molecular clearance of Babesia parasites, a key secondary endpoint. Following its review, the DSMB recommended completing the initially planned enrollment of 33 patients. As of October 1, 2026, the Company had enrolled 30 subjects. Due to the marginal impact an additional three subjects would have on power to detect a difference on the study endpoints and the seasonality of babesiosis and its potential to delay unblinding by a year if additional subjects were to be recruited, the Company intends to proceed with final analysis of the enrolled population. The DSMB’s recommendation does not establish whether the study met its endpoints; those results will be determined following unblinding and final analysis. The DSMB analysis did not identify any safety issues.

A growing body of published case reports suggests that tafenoquine, administered in combination with atovaquone-containing regimens for at least eight weeks, may achieve a high cure rate in high-risk patients with treatment-refractory, relapsing babesiosis. Consistent with these reports, the Company has confirmed molecular cure, using a highly sensitive nucleic acid amplification test (NAT), in the first three patients enrolled in its expanded access study of tafenoquine combined with atovaquone-containing regimens in relapsing, treatment-refractory babesiosis (“Expanded Use in Persistent B. Microti Babesiosis” — NCT06478641). Final screening data from two additional patients are expected in early November 2026. Irrespective of the ultimate results of the severe babesiosis study to be reported in January, the Company believes an approval pathway based on case reports in the treatment-refractory population is possible.

The Company intends to request a pre-sNDA meeting with FDA to discuss the clinical evidence and data requirements for an sNDA submission for tafenoquine treatment of babesiosis. Should the data package be supported by literature and expanded access cases only, the Company plans to ask FDA to consider NAT-based molecular clearance as a surrogate endpoint reasonably likely to predict clinical benefit, potentially supporting an accelerated approval pathway. The Company would also propose a post-approval confirmatory study in an appropriate patient population. The availability of an accelerated approval pathway and the adequacy of the submission will be subject to FDA review.

No FDA-approved treatment or vaccine exists for human babesiosis. While tafenoquine is approved for the prevention of malaria, it is not currently approved by FDA for the treatment or prevention of babesiosis.

About Babesiosis

Babesiosis is a tick-borne illness caused by Babesia parasites that develop and multiply in red blood cells. It is often found as a co-infection of Lyme disease. Symptoms include fevers, chills, sweats, and fatigue. In severely immunocompromised patients, standard antimicrobial regimens can fail to clear infection, resulting in relapsing disease that may persist for months or years and has been associated with the emergence of antimicrobial-resistant Babesia strains. Incidence of babesiosis is rapidly rising, particularly in the Northeast, and the Centers for Disease Control and Prevention has advised that emergency room visits for tick bites are currently at historically high levels in many regions of the U.S.

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company won U.S. Food and Drug Administration approval of its lead product, ARAKODA^® (tafenoquine), for malaria prevention in 2018 and currently has 3 active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA^® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Media Contact:

Kristen Landon kristenlandon@60degreespharma.com

Investor Contact:

Patrick Gaynes patrickgaynes@60degreespharma.com

Two autonomous patrols lead the race, highlighting the operational readiness of UAE-developed autonomous robotics across urban and community environments

DUBAI, United Arab Emirates, Oct. 06, 2026 (GLOBE NEWSWIRE) — Micropolis Robotics (NYSE American: MCRP), a UAE-based developer of autonomous robotics and Physical AI solutions, participated in the second edition of the “Proud of UAE” Cycling Race organized by Dubai Police, with two DPR2 Autonomous Patrols (Dubai Police Robot 2) leading the cyclists at the front of the race.

The 80-kilometer race was organized by Dubai Police in cooperation with the UAE Cycling Federation, Dubai Sports Council and Dubai’s Roads and Transport Authority. The event formed part of a broader program of sporting and national initiatives designed to promote community well-being, physical activity and national pride.

The participation of the DPR2 Autonomous Patrols demonstrates how autonomous systems engineered for demanding public-safety and security applications can operate across a growing range of real-world environments. Their presence in a public sporting event also reflects the increasing integration of autonomous technology into urban and community settings, operating alongside people as part of everyday city life.

“Participating in the Proud of UAE race is particularly meaningful because it brings our technology directly into the community, operating in a real-world environment alongside Dubai Police and the public,” said Fareed Aljawhari, Founder and Chief Executive Officer of Micropolis Robotics. “Our strategic partnership with Dubai Police has enabled us to develop autonomous systems around real operational requirements. Every new application allows us to demonstrate the versatility and operational readiness of these technologies as we expand their potential across public safety, security, infrastructure and urban operations.”

The participation builds on Micropolis’ strategic partnership with Dubai Police to develop and advance autonomous robotic systems for public safety and urban security.

The DPR2 combines autonomous navigation, intelligent perception, 360-degree environmental awareness and advanced connectivity for operations across public safety, security and urban environments.

The technology has progressed from development and real-world testing to active field operations. Last year, the first deployment entered operational service at Global Village, establishing a foundation for the continued advancement and broader application of the platform.

The participation of the new DPR2 Autonomous Patrols in the Proud of UAE race builds on that progress, demonstrating the technology in another active, public-facing environment alongside Dubai Police and the community.

Micropolis designs, develops and manufactures its robotic technologies in the UAE, integrating autonomous mobility, artificial intelligence, mechatronics and connected systems into Physical AI platforms built for real-world operations.

About Micropolis AI Robotics

Micropolis Robotics is a UAE-based company specializing in the design, development, and manufacturing of unmanned ground vehicles (UGVs’), AI systems, and smart infrastructure for urban, security, and industrial applications. The Company’s vertically integrated capabilities cover everything from mechatronics and embedded systems to AI software and high-level autonomy.

For more information, please visit www.micropolis.ai.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “will”, “should”, “can have”, “likely” and other words and terms of similar meaning. Forward-looking statements represent Micropolis’ current expectations regarding future events and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those implied by the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Contact: Info@Micropolis.ai

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c7a863c9-6c19-4cb7-ae0c-12e38689d983

The Master Services Agreement is expected to add $24 million in new annual contracted revenue bringing the Company’s projected annual revenue to $47 million.

DOVER, Delaware, Oct. 06, 2026 (GLOBE NEWSWIRE) — Alpha Compute Corp. (Nasdaq: ALP) (“Alpha Compute” or the “Company”), a vertically integrated leader in Sovereign Super Intelligence, today announced the signing of a binding contract on September 30, 2026 for its ALPHA-02 cluster, delivering a state-of-the-art high density NVIDIA B300 GPU deployment located in a 100% hydropowered data center in Sweden.

The ALPHA-02 cluster delivers next-generation NVIDIA B300 compute capacity, purpose-built to accelerate high-density AI training and inference workloads. Securing this binding offtake agreement ahead of the cluster’s full deployment secures long-term utilization and highlights the sustained, escalating enterprise demand for sovereign, high-performance computing.

“Signing this agreement reflects our commitment to working closely with our clients to deliver tailored high-performance compute solutions that meet every technical and operational requirement,” said Yury Mitin, Chief Business Development Officer at Alpha Compute.

“Signing two major contracts over the past two quarters highlights the tremendous dedication and operational excellence of our team and key partners,” said Brittany Kaiser, Chief Executive Officer. “By combining seamless delivery with deep technical capabilities, we ensure our clients receive the enterprise-grade performance and reliability required for their most demanding AI workloads.”

About Alpha Compute Corp.
Alpha Compute Corp. (Nasdaq: ALP) is a vertically integrated technology company delivering High Performance Computing (HPC) and AI Confidential Compute. Alpha Compute’s mission is to empower clients, subsidiaries, and partners across critical sectors, including finance, defense, intelligence, and media with the essential framework required for secure, confidential computing environments. Alpha Compute operates globally with offices in New York, Los Angeles, Miami, Amsterdam, and Toronto. Alpha Compute is a proud founding partner of the Right2Compute Coalition. 

For more information, please visit www.alphacompute.ai or www.right2compute.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements other than statements of historical fact including those preceded by, followed by, or incorporating words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “projects,” “plans,” “may,” “will,” “potential,” “continues,” or similar expressions are forward-looking statements. Forward-looking statements in this release include, without limitation, statements regarding the expected revenue, financial projections, and economic impact of the ALPHA-02 offtake agreement; the anticipated timeline, performance, and capabilities of the ALPHA-02 and ALPHA-01 clusters; expected enterprise demand for high-density AI compute capacity; and Alpha Compute’s broader expansion and operational strategy across North America and Europe.

These statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Risks include, but are not limited to: supply chain disruptions affecting hardware delivery and deployment; changes in enterprise demand for AI computing; delays in infrastructure buildouts; regulatory developments regarding AI and data sovereignty; and general economic conditions. Alpha Compute expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect any change in expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.

Investor & Media Contact
Alpha Compute Corp.
ir@alphacompute.ai
www.alphacompute.ai

CONTACT: ir@alphacompute.ai